MISSISSAUGA, ON, June 14 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN - News; TSX:VAS - News), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that the pivotal phase III ACCLAIM trial of its Celacade(TM) technology in advanced chronic heart failure has been accepted for presentation at a late breaking clinical trial Hot Line Session of the World Congress of Cardiology 2006, being held from September 2-6 in Barcelona, Spain. The World Congress of Cardiology 2006 brings together the XVth World Congress of Cardiology of the World Heart Federation and the 2006 Congress of the European Society of Cardiology the largest medical meeting in Europe, with more than 25,000 attendees expected.
